CSU commonly refers to chronic spontaneous urticaria, also known as chronic idiopathic urticaria. It is characterized by recurrent wheals, angioedema, or both lasting for more than six weeks. The condition is associated with mast-cell mediated inflammation and can substantially affect quality of life.
Two studies examined blood biomarkers for omalizumab response in chronic spontaneous urticaria. Basophil histamine content did not predict response, while higher baseline monocyte counts were linked to complete remission in a 52-patient retrospective analysis.
Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.
The University of Colorado Anschutz School of Medicine rose to No. 21 nationally with nearly $314 million in NIH funding, while Colorado School of Public Health climbed to No. 17 with over $22 million. Wayne State University School of Medicine ranked 73rd with $61.6 million.
Novartis announced positive topline results from its Phase III RemIND trial of remibrutinib in chronic inducible urticaria, meeting the primary endpoint for the three most prevalent types of the condition with significantly higher complete response rates versus placebo.
Novartis reported positive Phase III RemIND trial results showing remibrutinib achieved complete response in three types of chronic inducible urticaria. The company has submitted a supplemental New Drug Application to the FDA for symptomatic dermographism.
Novartis announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria, meeting the primary endpoint for three prevalent CIndU types with significantly higher complete response rates versus placebo at Week 12.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06795373 |
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria |
WITHDRAWN | PHASE2 |
